At a glance
ClinicalIndex Comparison RecordN/ACompleted· 99 enrolled
Drug / intervention
varenicline +1 moredrug
Likely dose
varenicline 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Characterizing Alpha5 Nicotinic Receptors in Alcohol and Nicotine Dependence
In Brief
A clinical study evaluating varenicline and placebo for Substance Dependence. Completed, enrolled 99 participants across 1 site.
Detailed Summary
Purpose: This is an outpatient, randomized, double-blinded, placebo-controlled study in which either varenicline (twice daily) or placebo will be administered over a 12 week study period to examine genetic influences on treatment response to varenicline for reduction of hazardous drinking.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSubstance Dependence
CountriesUnited States
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2009
Enrollment StartJan 2010
Primary CompletionJul 2011
Study CompletionJun 2012
TodayJul 2026
First PostedNov 11, 2009
Enrollment StartJan 1, 2010
Primary CompletionJul 1, 2011
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.6 years ago
Interventions
vareniclinedrug
12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
placebodrug
12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).